Aktienanalyse zu Genprex Inc (GNPX)GNPXGenprex Inc

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Genprex Inc is not a good buy right now due to its significant financial losses and poor performance metrics. The current price is $3.67, with a year-to-date change of -90.68%, indicating a severe decline. Additionally, the company has a negative net income for the last reported quarter of -4,467,219 USD, which raises concerns about its financial viability. The RSI is at 24.825, suggesting the stock is oversold, but this does not outweigh the risks involved. The main risk is the company's ongoing losses, with a forward P/E ratio of 0, indicating no earnings expected in the near future.

1 analysts cover GNPX: 1 rate it Buy, 0 Hold and 0 Sell.